BWA
WST icon

Basecamp Wealth Advisors’s West Pharmaceutical WST Stock Holding History

Basecamp Wealth Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2K Hold
59
– – ﹤0.01% 792
2026
Q1 		$14.8K Sell
59
-20
-25% -$4.98K ﹤0.01% 911
2025
Q4 		$21.7K Buy
+79
New +$21.6K ﹤0.01% 765

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Basecamp Wealth Advisors's WST Position: Q2 2026 in Review

Basecamp Wealth Advisors held its West Pharmaceutical (WST) position steady in Q2 2026 at 59 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #792.

Basecamp Wealth Advisors first reported a position in WST in Q4 2025 and has held it in 3 quarters since. The position peaked at $21.7K in Q4 2025. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Basecamp Wealth Advisors held 59 shares of West Pharmaceutical worth $21.2K as of Q2 2026.
  • Basecamp Wealth Advisors left its West Pharmaceutical share count unchanged in Q2 2026.
  • West Pharmaceutical made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #792 holding.
  • Basecamp Wealth Advisors first reported a position in West Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's West Pharmaceutical position peaked at $21.7K in Q4 2025.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.